MannKind Breathing Easier After FDA Diabetes Safety Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Trials for inhaled insulin Afresa were already designed to satisfy new cardiovascular risk guidelines, firm says.
You may also be interested in...
NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner
Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.
NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner
Despite safer-seeming profile, many skeptical of Afresa after flameout of Pfizer’s product.
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development